B. Neyns

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

W. Scheithauer, E. Van Cutsem, B. Neyns, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

B. Neyns, A. Michotte, O. Tynninen, 2011, Journal of Neuro-Oncology.

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

E. Van Cutsem, M. Overman, S. Lonardi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

R. Dummer, E. Rozeman, H. Schmidt, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

E. Van Cutsem, H. Lenz, B. Neyns, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma

A. Michotte, V. Verschaeve, M. Mercier, 2017, Journal of Neuro-Oncology.

Phase II study of helical tomotherapy for oligometastatic colorectal cancer.

B. Neyns, D. Verellen, M. Ridder, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma

I. Salmon, B. Neyns, A. Michotte, 2017, Journal of Neuro-Oncology.

Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity.

B. Neyns, M. Maio, S. O’Day, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

J. Menten, R. Sciot, B. Neyns, 2009, European journal of cancer.